Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Newly Identified ‘Lucy’s Hunter’ Was a 15-Foot Crocodile Lurking in Ancient Ethiopia - 2Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
- 3How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- 4I'm a woman who's into weightlifting. Was I man enough for the creatine-packed 'Man Cereal'?
- 5Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- Israel approves death penalty law for Palestinians convicted of attacks
- Winter storms blanket the East, while the U.S. West is wondering: Where’s the snow?
- African nations push to recognize crimes of colonialism in Algeria
- Former Peruvian President Pedro Castillo sentenced for conspiracy
- From Dread to Certainty: Individual Accounts of Strengthening
- Why haven’t humans been back to the moon in over 50 years?
- The Most Famous Virtual Entertainment Powerhouses of the Year
